Browsing Tag
SC0062 trial
1 post
BioCity’s SC0062 secures second breakthrough therapy designation in China for diabetic kidney disease
BioCity Biopharma’s ETA-selective SC0062 earns second Breakthrough Therapy Designation in China for diabetic kidney disease, reinforcing its CKD potential.